Osipova Vera Valentinovna

Professional skills

Cephalgology is a branch of neurology that specializes in the study and treatment of headaches.

• Diagnosis, treatment and prevention of migraine, tension headache, abuse, cluster and other forms of headache.
• Prevention and treatment of headaches and cerebrovascular diseases in the elderly (vertebrobasilar insufficiency, dyscirculatory encephalopathy, etc.).
• Diagnosis and treatment of psychovegetative disorders (panic attacks (vegetative crises), psychosomatic disorders, emotional disorders (depression, anxiety disorders).

Professional Development

• PhD thesis: “Clinical-psychovegetative characteristics and differentiated therapy of various forms of migraine” (1991), MD: “Migraine, clinical and psychological analysis, quality of life, comorbidity, therapeutic approaches” (2003 .).
• European Headache Federation Award G. Kautchishvili for the research work "Psychovegetative approaches to migraine" (1993).
• Participation in clinical trials:
  - Researcher (4 RCTs).
  - Principal Investigator (1 RCT).
• Lecturer of the school of GB in the Russian Federation and Eastern Europe, the school of the European Academy of Neurology.
• Publications:
  - Russian - about 200.
  - Foreign - more than 60.
  - Monographs - 6.
• Member of the team of authors of the national leadership Neurology.
• Translator into Russian of the International Classification of Headache, version 2 (ICHD-2, 2004).
• Coordinator and editor of the translation into Russian of the International Classification of Headache, version 3 (ICHD-3, 2018).
• Reviewer for Cephalalgia, European Journal of Headache and Pain, Neurological Sciences.
• Member of the team of authors of Clinical guidelines for migraine and tension headache of the Ministry of Health of the Russian Federation (2016-2022).
• 1996 - 1997 – researcher – A Multi-Center, Double-Blind. Placebo Controlled. Study of Efficacy and Safety of Zolmitriptan (2.5-5.0 mg) in the Acute Treatment of Migraine Attacks.
• 2006 - 2008 – Protocol BC-Fv-05 FREEDOM. Researcher – A Prospective Multi-Center, Double-Blind. Placebo Controlled. Study of Efficacy and Safety of Frovatriptan (2.5-5.0 mg) in the Acute Treatment of Migraine Attacks.
• 2009 - 2010 – Protocol MK-0974-031. Investigator – A Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura.
• 2009 - 2010 – Protocols MK-0974-031/34. Investigator – Protocol MK-0974-034 “A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 (Rizatriptan) in the Treatment of Acute Migraine in Patients With Stable Vascular Disease.
• 2015 – 2017 – Protocols AMG 334 20120296 / 97. Principal Investigator – A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention.

Checking children: no.

• Russian